4D Molecular Therapeutics reported cash from operations of -$70.00M and free cash flow of -$70.00M for the quarter ended Jun 2026, down 61.4% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||
| Net Income | -22.23M | -25.08M | -26.29M | -28.09M | -25.70M | -27.38M | -28.66M | -29.62M | -10.10M | -32.27M | -32.39M | -34.91M | -43.84M | -49.65M | -48.04M | -54.60M | -56.85M | 19.42M | -68.76M | -72.77M | ||||||
| Depreciation and DepletionDep. & Depletion | 0.40M | 0.40M | 0.40M | 0.50M | 0.50M | 1.00M | 1.00M | 1.10M | 1.10M | 1.30M | 1.20M | 1.20M | 1.20M | 1.20M | 1.30M | 1.30M | 1.30M | 1.30M | 1.30M | 1.30M | ||||||
| Share-based CompensationStock Comp. | 3.92M | 3.73M | 3.93M | 4.32M | 4.52M | 4.35M | 4.22M | 4.97M | 4.56M | 5.91M | 5.97M | 6.07M | 6.49M | 7.58M | 6.99M | 4.96M | 4.52M | 5.55M | 4.45M | 5.88M | ||||||
| Gains from Sales and DivestituresGains Divest | ||||||||||||||||||||||||||
| Cash from OperationsCash from Ops. | -15.72M | -21.84M | -23.55M | -19.90M | -21.02M | -22.21M | -27.91M | -22.07M | -1.17M | -24.65M | -29.09M | -30.24M | -29.39M | -45.86M | -47.76M | -43.38M | -46.50M | 28.55M | -68.12M | -70.00M | ||||||
| Depreciation, Depletion & Amortization | ||||||||||||||||||||||||||
| Depreciation & Amortization (CF)Dep. & Amort. | 0.38M | 0.39M | 0.41M | 0.47M | 0.52M | 1.01M | 1.03M | 1.08M | 0.99M | 1.10M | 1.17M | 1.19M | 1.19M | 1.10M | 1.05M | 1.17M | 1.26M | 1.22M | 1.27M | 1.28M | ||||||
| Change in Working Capital | ||||||||||||||||||||||||||
| Change in ReceivablesChange Receivables | -0.43M | -0.74M | -0.05M | |||||||||||||||||||||||
| Change in Account PayablesChange Payables | 0.80M | 1.66M | -1.68M | 0.23M | -1.70M | 1.51M | -0.33M | 0.95M | 1.37M | -1.09M | 0.70M | -0.79M | -0.51M | 1.46M | -0.23M | 4.55M | -1.84M | 4.30M | 3.53M | -4.06M | ||||||
| Change in Accured ExpensesChange Accured Exp. | 1.06M | 0.54M | -1.07M | 0.65M | 1.08M | 1.82M | -3.40M | 1.16M | 3.61M | 2.00M | -2.39M | 3.17M | 8.11M | -2.37M | -2.31M | 3.11M | 4.98M | 2.37M | -4.12M | 6.54M | ||||||
| Other Working Capital ChangesOther WC Changes | -0.62M | 0.35M | -1.22M | -1.44M | -1.03M | 0.56M | -0.44M | -0.10M | 2.16M | -3.08M | 1.32M | 1.01M | -0.15M | 1.40M | 2.78M | 2.35M | -0.01M | -0.19M | 3.99M | 6.53M | ||||||
| Investing Activities | ||||||||||||||||||||||||||
| Capital ExpendituresCapex | 2.63M | 5.10M | 6.41M | 2.07M | 1.96M | 1.09M | 1.01M | 0.81M | 0.41M | 0.55M | 0.71M | 0.35M | 1.78M | 0.95M | 0.63M | 0.07M | -0.09M | -0.07M | ||||||||
| Cash from Investing ActivitiesCash from Investing | -139.01M | -32.29M | -54.11M | 57.47M | 15.37M | -35.78M | 43.13M | 49.29M | 29.98M | -6.68M | -263.26M | -73.54M | 27.30M | 7.06M | 31.95M | -13.85M | 17.78M | -128.85M | 68.89M | 25.54M | ||||||
| Financing Activities | ||||||||||||||||||||||||||
| Cash from Financing ActivitiesCash from Financing | 1.98M | 116.14M | 0.63M | -0.05M | 0.46M | 2.05M | 10.99M | 130.52M | 10.56M | 4.76M | 318.83M | 17.25M | 0.57M | 0.60M | 0.86M | 0.12M | 111.98M | 11.48M | 42.34M | |||||||
| Change in Capital Stock | ||||||||||||||||||||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 114.30M | 0.88M | -0.88M | 0.47M | -0.47M | 1.42M | -0.76M | 147.69M | 0.00M | 3.11M | 328.30M | 0.00M | 9.81M | 21.84M | ||||||||||||
| Additional items | ||||||||||||||||||||||||||
| Change in Cash | -152.75M | 62.01M | -77.03M | 37.51M | -5.19M | -55.95M | 26.22M | 157.74M | 39.37M | -26.57M | 26.49M | -86.53M | -1.52M | -38.20M | -15.81M | -56.37M | -28.60M | 11.69M | 12.25M | -2.12M | ||||||
| Free Cash FlowFCF | -18.36M | -26.93M | -29.96M | -21.97M | -22.98M | -23.31M | -28.92M | -22.87M | -1.58M | -25.20M | -29.80M | -30.59M | -31.17M | -46.81M | -48.39M | -43.44M | -46.41M | 28.62M | -68.12M | -70.00M | ||||||
| Net Cash FlowNCF | -152.75M | 62.01M | -77.03M | 37.51M | -5.19M | -55.95M | 26.22M | 157.74M | 39.37M | -26.57M | 26.49M | -86.53M | -1.52M | -38.20M | -15.81M | -56.37M | -28.60M | 11.69M | 12.25M | -2.12M |
Pull 4D Molecular Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=FDMT&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "FDMT", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=FDMT&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();